Semaglutide, a glucagon like peptide-one (GLP-one) receptor agonist, is obtainable as monotherapy in equally subcutaneous as well as oral dosage variety (to start with accredited oral GLP-one receptor agonist). It has been approved as a 2nd line cure option for better glycaemic Management in variety 2 diabetes and presently under https://greatr909iue3.newbigblog.com/profile